Opioid Post-marketing Studies: Can Sponsors Work Well Together Again?
Executive Summary
FDA wants to get a handle on how long-term use of long-acting pain killers relates to abuse and misuse; the agency also is requiring labeling changes that remove “moderate” pain from the products’ indication.
You may also be interested in...
Endo's Belbuca Is First Buccal Film In Extended-Release Opioid Class
While Belbuca represents a new formulation, it does not contain the abuse-deterrent properties that FDA has been encouraging.
Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment
REMS assessment schedule for the long-acting/extended release opioid products reflects the large number of drugs, prescribers and patients involved in the risk management program and the time needed to put all its components in place.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.